# CURRICULUM VITAE

# TODD KEN HORIUCHI, M.D., FCCP

**Present Business Address:**

**Hautamaki & Horiuchi**
**Personal Physicians of Sarasota**
**1843 Floyd Street**
**Sarasota, FL 34239**
**Telephone: 941-951-3920**
**Fax: 941-952-3922**
(e-mail: tkhoriuchi@aol.com)

**Prior Business Address:**

Lung Associates of Sarasota
Associates in Sleep Medicine
1895 Floyd St.
Sarasota, FL 34239
Telephone: 941-366-5864

**Marital Status:** Married, 3 Children

**Present Position:** Physician, Private Practice

**Faculty Appointment:** Clinical Assistant Professor, Department of Clinical Sciences (Internal Medicine, Pulmonary & Critical Care Medicine), Florida State University College of Medicine

**Education:**

B.A. (Biology), Washington University, St. Louis, MO
August 1987-May 1991
Cum Laude Graduate
Scholars Program in Medicine

M.D., Washington University School of Medicine, St. Louis, MO
August 1991-May 1995

**Residency:** Internal Medicine Residency Program, University of Texas Southwestern Medical Center, Dallas, TX
July 1995-June 1998

**Fellowship:** Pulmonary & Critical Care Medicine Fellowship Program, Washington University School of Medicine, St. Louis, MO
July 1998-June 2001

**Medical Licensure/ Certification:** United States Medical Licensing Examination
Step I (June 1994 )/ Step II (March 1995 )/Step III (May 1996) - Passed

Texas State Board of Medical Examiners-Medical License - expired 2/28/99
Texas Medical Jurisprudence Examination - May 1996 - Passed

Missouri State Board of Registration for the Healing Arts-Medical License - 1998-2001

Florida State Board of Medicine License – 2001 – present

Hawaii State Board of Medicine License – 2001 – present

American Board of Internal Medicine - Certification in Internal Medicine - August 1998
American Board of Internal Medicine - Certification in Pulmonary Diseases – November 2000
American Board of Internal Medicine – Certification in Critical Care Medicine – 2001
American Board of Sleep Medicine – Certification in Sleep Medicine – 2003

**Organizations:**

American College of Physicians - American Society of Internal Medicine
American College of Chest Physicians
American Thoracic Society
Society of Critical Care Medicine
American Academy of Sleep Medicine
Best Doctors in America

**Committees:**

Special Care (ICU) Committee, Sarasota Memorial Hospital, 2001 – present
Mission & Planning Committee, Sarasota County Public Hospital Board, 2008—present
Chairman, Pharmacy & Therapeutics Committee, Sarasota Mem. Hospital, 2003–present
Chairman, Department of Medicine, Sarasota Memorial Hospital, 2006—2007

**Educational Activity:**

Course Founder/Director, Pulmonary Pathology Conference, Washington University School of Medicine, 1999-2001
Course Co-Director, Pulmonary and Critical Care Medicine Division Grand Rounds, Washington University School of Medicine, 2000-2001
Instructor, Introduction to Clinical Medicine Course, University of Texas Southwestern Medical School, 1996-1998
Instructor, Clinical Skills Course, Washington University School of Medicine, 2000-2001

**Clinical Activity:**

Staff Physician, Sarasota Memorial Hospital, Sarasota, FL, 2001-present
Staff Physician, Doctors Hospital of Sarasota, Sarasota, FL, 2001-2006
Staff Physician, HealthSouth Rehabiliation Hospital of Sarasota, 2001-present
Critical Care Physician, Bone Marrow Transplant Unit, Washington University School of Medicine, St. Louis, MO, 1999-2001
Critical Care Physician, Christian Hospital Northeast, Hazelwood, MO, 1999-2001
Critical Care Physician, Barnes-Jewish Hospital-St. Peters, St. Peters, MO, 1999-2001
Admitting Physician, Emergency Department, Dallas Veterans Administration Medical Center 1997-1998

**Publications:**

Cohen, L, Xueping, E, Tarsi, J, Ramkumar, T, Horiuchi, TK, Cochran, R, DeMartino, S, Schechtman, KB, Husain, I, Holtzman, MJ, Castro, M. Epithelial Cell Proliferation Contributes to Airway Remodeling in Severe Asthma. Am J Respir Crit Care Med 2007.

Horiuchi, T, Castro, M. Inhaled Steroids-The Mainstay of Asthma Therapy. J Resp Dis 2001

Horiuchi, T, Castro, M. The Pathobiologic Implications for Treatment: Old and New Strategies in the Treatment of Chronic Asthma. Clinics in Chest Medicine. 21:381-395, 2000.

Walter, MJ, Morton, JE, Kajiwara, N, Palamand, D, Gutierrez-Ramos, JC, Horiuchi, T, Castro, M, Holtzman, MJ. Segregating acute airway inflammation/hyperreactivity from chronic remodeling/hyperreactivity phenotypes induced by paramyxoviral infection. J Exp Med 2000

Herzog, TJ, Horiuchi, TK, Williams, S, Camel, HM, Mutch, DG. Growth Modulatory Effects of Granulocyte-Macrophage Colony-Stimulating Factor on Human Cell Lines Derived from Gynecologic Malignancies. American Journal of Obstetrics and Gynecology. 174:1:161-168, 1996.

Powel, CB, Horiuchi, T, Kao, MS, Collins, JL. Interferon Alfa Activates a Lytic Mechanism in Ovarian and Cervical Carcinoma Cells. American Journal of Obstetrics and Gynecology. 169:3:661-667, 1993.

**Abstracts:**

Harrell, R, Burgman, K, Grimes, C, Anderson, R, Hurwitz, K, Horiuchi, T, Fleegler, B. Benchmarked Community Hospital Ventilator Management: The Effect of Multidisciplinary Protocols on Ventilator Days in an Open Medical/Surgical Intensive Care Unit. Chest 130 (4):133S. 2006.

Grimes, C, Anderson, R, Horiuchi, T, Concha, C, Fleegler, B, Hurwitz, K. Resuscitative Hypothermia after Cardiac Arrest: Performance in a Community Hospital. Chest 128 (4):167S. 2005.

Horiuchi, TK, Castro, M, Morton, JD, Bloch, SR, Holtzman, MJ. Airway Remodeling Following Inhaled Corticosteroid Withdrawal in Asthma. ATS 2001-97th International Conference of the American Thoracic Society. San Francisco, CA. May 2001. (Abstract# 222368).

**Research:**

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A one-year randomized, double-blind, placebo and active-controlled parallel design safety and efficacy comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT® (CFC) Inhalation Aerosol in patients with COPD

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Prospective, randomized, double-blind, multicenter outpatient trial comparing the safety and efficacy of moxifloxacin 400 mg PO QD for 5 days vs. azithromycin 500 mg PO loading dose on day 1, then 250 mg PO QD for 4 days for the treatment of Acute Exacerbations of Chronic Bronchitis ( The QUICK Study) STUDY NUMBER: 100314

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Ariflo (15 mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 00-PULM-51

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) Prospective, randomized, double-blind study comparing Faropenem Daloxate 300mg PO BID for 5 days with Azithromycin for 5 days (500mg PO day 1, then 250 mg PO OD days 2-5) in the treatment of patients with acute exacerbation of chronic bronchitis. Bayer Protocol 100291 #00-PULM-39.

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Randomized, Open-Label, Pilot Assessment Of The Effect Of Protonix® Iv For Injection (Pantoprazole Sodium) On Gastric Ph In ICU patients.

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Multicenter, Randomized, Open-Label Study Comparing The Efficacy And Safety Of Once Daily (O.D.) Org 31540/Sr90107a Versus Adjusted-Dose Intravenous (Iv) Unfractionated Heparin (Ufh) In The Initial Treatment Of Acute Symptomatic Pulmonary Embolism (PE) 01-PULM-03

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Double-Blinded, Placebo-Controlled, Parallel Group Study of Uridine 5-Triphosphate (UTP) Solution for Inhalation as an Adjunct in the Diagnosis of Lung Cancer by Sputum Cytology (Inspire Lung CA) 01-PULM-12

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) Title: A randomized, double-blind, placebo-controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). SPONSOR: Boehringer Ingelheim Pharmaceuticals, Inc. 02-PULM-21

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A multicentre, randomized, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (Seretide™/Viani™/Advair™) 50/500µg bd, salmeterol 50µg bd and fluticasone propionate 500µg bd, all delivered via the Diskus/™Accuhaler™ inhaler, on the survival of subjects with chronic obstructive pulmonarydisease (COPD) over 3 years of treatment. 02-PULM-20

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) MI-CP079 "Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients with Unresectable Non-Small Cell Lung Cancer"

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies PIPF-012

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) SCO40041: A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effects of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID via DISKUS versus Salmeterol 50mcg BID via DISKUS on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD).

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) Endobronchial Valve for Emphysema Palliation Trial (VENT) 03-PULM-34

Sub-Investigator: (Clinical Research Center of Sarasota Memorial Hospital) A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects with Severe Hyperinflation Protocol Number 30 (EASE) Sponsor: Broncus Technologies, Inc.

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive

Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative Pneumonia

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) Protocol No.01-04-TL-242-011: A Pivotal, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis.Sponsor: Takeda Global Research & Development Center, Inc.

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) AC-052-419: An Open-label, Multi-Center Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) PIPF-002 An Open-Label, Phase 2 Study of the Safety and Efficacy of Oral Pirfenidone in Patients with Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-006)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) SCO100250: A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS™ Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis PIPF-016

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2) Protocol GS-US-219-0104

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) Protocol D589CC00003: A Phase IIIB, 12-Month, Double-blind, Double-dummy, Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 µg x 2 Actuations Twice-daily and 80/4.5 µg x 2 Actuations Twice-daily Compared to Formoterol TBH 4.5 µg x 2 Inhalations Twice-daily in COPD Subjects.

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) GS-US-322-0207

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) BI 1199.187 A double blind randomized placebo controlled trial evaluating the

effect of oral nintedanib 150 mg twice daily on high resolution computerized tomography quantitative lung fibrosis score, lung function, six minute walk test distance and St. George's Respiratory Questionnaire after twelve months of treatment in patients with Idiopathic Pulmonary Fibrosis with continued evaluations over a period of up to eighteen months

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone Protocol Number: PIPF-031

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) CTT116855: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital) BAY q 3939/15626: Randomized, double-blind, placebo-controlled, multicenter study comparing ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis

Principal Investigator (Clinical Research Center of Sarasota Memorial Hospital) MA29895: An Exploratory Multicenter, Open-Label, Single Arm Study Of The Safety And Tolerability Of Pirfenidone (ESBRIET®) In Combination With Nintedanib (OFEV®) In Patients With Idiopathic Pulmonary Fibrosis